Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sevoflurane + nitrous oxide + oxygen
- Development stage
- Phase 4
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
A combination anesthetic mixture consisting of sevoflurane (a volatile anesthetic agent), nitrous oxide (an inhalational anesthetic), and oxygen. This combination is commonly used for inhalational induction and maintenance of general anesthesia, particularly in pediatric patients. The mixture provides rapid induction due to sevoflurane's pleasant non-irritating odor and low blood-gas solubility, while nitrous oxide is sometimes used to potentially enhance alveolar uptake of sevoflurane. It leverages the properties of each component to achieve effective anesthesia.
02
Targets
GABRR (GABA-A receptor subunit rho)NMDAR (Glutamate receptor ionotropic, NMDA)GABA-B (Gamma-aminobutyric acid receptor type B)
Beyond the preview
Go deeper on sevoflurane + nitrous oxide + oxygen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sevoflurane + nitrous oxide + oxygen.